Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Payables (2016 - 2025)

Historic Payables for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $22.3 million.

  • Regenxbio's Payables rose 1405.59% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year increase of 1405.59%. This contributed to the annual value of $22.8 million for FY2024, which is 5.27% up from last year.
  • Regenxbio's Payables amounted to $22.3 million in Q3 2025, which was up 1405.59% from $21.7 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Payables ranged from a high of $31.4 million in Q1 2024 and a low of $9.4 million during Q2 2021
  • Over the past 5 years, Regenxbio's median Payables value was $21.7 million (recorded in 2025), while the average stood at $19.9 million.
  • In the last 5 years, Regenxbio's Payables surged by 13898.31% in 2022 and then tumbled by 3926.52% in 2025.
  • Regenxbio's Payables (Quarter) stood at $11.4 million in 2021, then soared by 138.98% to $27.2 million in 2022, then fell by 16.27% to $22.8 million in 2023, then increased by 0.05% to $22.8 million in 2024, then fell by 2.33% to $22.3 million in 2025.
  • Its Payables was $22.3 million in Q3 2025, compared to $21.7 million in Q2 2025 and $19.0 million in Q1 2025.